The presence of high numbers of intraepithelial, but not stromal, CD8-positive T lymphocytes was of uni- and multivariate prognostic benefit for stage III ovarian cancer patients, especially in the large sub-group of patients receiving adjuvant paclitaxel/carboplatin therapy. This evidence concerns the gene CD8A and ovarian cancer.